shutterstock_31312693-300x200Israel is home to more than 750 medical device companies, 300 pharmaceutical/biotech companies, and 170 other life science or healthcare IT companies. David Dykeman, co-chair of Greenberg Traurig’s  Life Science & Medical Technology Group, describes Israel as a “biomedical and healthcare powerhouse.”

David recently led a delegation of New England executives and investors from the biomedical, healthcare and life science sectors to spend three days exploring Israeli  innovation and commercialization, learning about Israel’s cutting edge medical technology and investment trends, and speaking with executives of Israeli companies. In return, Israeli executives learned more about why Boston – with its own tech innovation, renowned universities and venture capital investors – is a natural fit for Israeli companies looking to enter the U.S. market.


Continue Reading New England Executives Get an Inside Look at Israeli Innovation

The 33rd Annual J.P. Morgan Healthcare Conference & Biotech Showcase was held in January in San Francisco, Calif. The conference is the biggest health care investing event of the year, attracting thousands of medical device, biotechnology, and pharmaceutical executives and investors in attendance from around the world. Numerous Israeli companies participated in the conference, including a group of seven health care technology companies that presented at the Health Evolution Summit, “Connecting Health Leaders.”

More than 30 Greenberg Traurig attorneys from offices around the world attended the conference to provide support to existing clients and forge new connections. In attendance from the firm’s Israel Practice were  Bob Grossman, co-chair of the Israel Practice, David Dykeman, co-chair of the firm’s Life Sciences & Medical Technology Group, and  Roman Fayerberg, an IP shareholder in the Boston office.


Continue Reading Greenberg Traurig Attorneys Participate in J.P. Morgan Healthcare Conference & Biotech Showcase